O n a world scale, in 2013, there have been >17 million cardiovascular deaths, one half of which attributable to ischemic heart disease. 1 More than 50% of cases of ischemic heart disease deaths presenting as sudden cardiac death have no history of symptoms heralding the critical event, 2 and most myocardial infarctions occur in low or moderate risk subjects (ie, in the largest segment of the general population). On a lifetime scale, the risk of myocardial infarction at the age of 40 years is 1 in 2 men and 1 in 3 in women. 3 These figures underline the potential relevance of timely screening and treatment of individuals at risk of cardiovascular disease.
The Framingham Risk Score or the recently developed risk calculator, which informs the American College of Cardiology/American Heart Association cholesterol guideline, 4 the HeartScore, 5 or the QRISK calculator, 6 are center pieces of current policies for cardiovascular risk assessment and for lipid-lowering treatment. Because in these calculators age is the most informative risk factor for the prediction of cardiovascular events, 7 these instruments have limited precision for the prediction of coronary atherosclerosis at individual level particularly in young subjects who have a low absolute risk for cardiovascular disease events. 8 Novel biomarkers measurable in plasma or serum have been intensively investigated to refine risk prediction in individuals at low or moderate risk, but the gain in prediction power by these biomarkers is just of modest degree. 9 Imaging biomarkers provide an estimate of the atherosclerotic burden in critical areas of the arterial system like the coronary circulation and may provide an integrated measure of life time exposure to risk factors. Among imaging markers of atherosclerosis assessment of vascular calcification, in particular of coronary calcification, is considered as the most valuable one because it outperforms other imaging techniques such as carotid intima media thickness. 10 Because coronary calcium reflects well the risk for coronary heart disease events and other major cardiovascular events, 11, 12 the coronary calcium score has gained momentum well beyond screening and risk prediction, and this biomarker has been increasingly adopted as a surrogate of clinical events in trials testing disparate interventions for the prevention of cardiovascular disease in various populations.
Vascular calcification is a hallmark in patients with chronic kidney disease (CKD), a population with a high cardiovascular risk, 13 and for this reason, CKD is the condition where the coronary calcium score and calcification at other sites of the cardiovascular system have been most frequently applied as a surrogate end point to investigate experimental treatments in CKD. The interest on coronary calcification as a surrogate end point is not fading. As on January 22, 2015, >100 clinical 4
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July 2015 trials adopting coronary calcification or calcification at other sites of the cardiovascular system (thoracic aorta or cardiac valves) as a primary or secondary end point were registered in clinicaltrials.gov. As alluded to before, metrics of coronary calcium accumulation may integrate temporal exposure to risk factors, and studies based on repeated measurements of coronary calcium may therefore constitute a surrogate of disease activity and of the associated risk. However, experimental models suggest that the progression of coronary calcification may not adequately reflect the evolution of underlying severity of atherosclerosis 14 and skeptical views 15 now counterbalance enthusiasm on the potential of this technique in cardiovascular research.
In this review, we will reappraise the validity of coronary calcification as a screening tool for cardiovascular prevention and as a surrogate end point in clinical trial. To this scope, we will face-to-face compare the methodological requisites demanded to biomarkers when applied for cardiovascular prevention and when used as surrogates of clinical end points with the actual performance of the coronary calcium score in screening studies and in clinical trials. This review revisits and integrates meta-analyses, which collated clinical trials aimed at assessing the usefulness of coronary calcification screening for motivating therapeutic interventions or clinical trials testing the effect of drug treatment on coronary calcification progression. Discussion of these clinical trials and meta-analyses will be preceded by a summary of the vascular biology of calcification and the quantification of calcification in the cardiovascular system and by a brief methodological account about the validity of biomarkers as screening tools or as surrogates in clinical trials (Appendix in the online-only Data Supplement).
Coronary Calcification as a Screening Test and as a Surrogate End Point in Clinical Research

Coronary Calcium as a Screening Test, Lifestyle, and Risk Factors Modification and Downstream Testing in Primary Prevention
It was claimed that adopting coronary calcium as a screening test is useful in primary prevention because it may have a favorable effect on lifestyle modification, risk factors, and downstream testing. Patients with measurable levels of coronary calcium may be more likely to start aspirin or lipidlowering medications 16 or to modify their dietary or physical exercise habits 17 when compared with those without visible coronary calcium. However, proof that a test improves clinical outcomes is now demanded to formally recommend the use of the same test in clinical practice. 9, 18 Most studies on this problem are observational in nature, and therefore the issue remains highly controversial. The 2010 guidelines of the American Heart Association and the American College of Cardiology recommended measurement of coronary calcium as a reasonable option for cardiovascular risk assessment in asymptomatic adults at intermediate risk (10%-20% 10-year risk) and as a perhaps reasonable option in patients at low-to-intermediate risk (6%-10% 10-year risk), but did not recommend this test in individuals at low risk (<6%). 19 These recommendations were class II B, ie, their usefulness was considered to be insufficiently assessed, and the same recommendations were based on evidence obtained in a limited population (data derived from single randomized studies or nonrandom studies 22 trial. Three trials reported a nonsignificant 15% increase in the probability of smoking cessation in individuals screened with the calcium score when compared with those not submitted to this test. In the EISNER trial, a higher calcium score associated with an increased prescription of lipidlowering medications and, conversely, the absence of calcium in the coronary arteries associated with fewer prescriptions of these medications. Furthermore, in this trial, small but significant reductions in systolic blood pressure (−2 mm Hg) and in low-density lipoprotein cholesterol (−4.3 mg/dL) were registered. However, in the meta-analysis, the pooled estimates of the drop in blood pressure (−0.23 mm Hg/−0.42 mm Hg) and low-density lipoprotein cholesterol (−0.23 mg/dL) were clinically trivial. Thus, the motivational benefit of coronary calcium screening seems to be modest at best. After this metaanalysis, in 2012, a nonrandomized screening intervention that tested the effect of risk evaluation by the coronary calcium and the HeartScore on the use of preventive treatments in 1075 Danish people 23 was published. At follow-up, 21% of patients with a high calcium score (n=462) and 19% of those with high HeartScore (n=233) received lipid-lowering treatment, whereas 25% and 32%, respectively, received antihypertensive treatment. The presence of a high calcium score was associated with an increased use of lipid-lowering treatment (odds ratio, 2.2; 95% confidence interval, 1.2-4.0), whereas the presence of a high HeartScore was associated with an increased use of lipid-lowering (odds ratio, 2.9; 95% confidence interval, 1.6-5.5) and antihypertensive drugs (odds ratio, 3.4; 95% confidence interval, 1.9-6.0), indicating that that the coronary calcium score was not superior to the HeartScore for these motivational outcomes. Therefore, this study provided further proof against the motivational usefulness of coronary calcium screening in primary prevention. A new meta-analysis on the same issue published in June 2014 24 included the Danish study 23 and trials considered in Whelton meta-analysis 21 and 12 observational studies. The conclusion of this meta-analysis was more optimistic than that of the previous one. 21 However, the apparent benefit of the calcium score for screening was entirely driven by the 12 observational studies. Observational studies looking at motivational outcomes, like those included in Mamudu meta-analysis, are particularly prone to bias, and their value is highly questionable. Therefore, the most recent meta-analysis 24 does not represent a solid gain in the evidence-based assessment of the usefulness of coronary calcium screening in primary prevention.
Techniques for estimating calcium content in the arterial wall are continuously being refined. Probably because of the unique propensity to calcification of CKD patients, the Agatston score performed well as a risk predictor in a recent subanalysis of the Multi-Ethnic Study of Atherosclerosis (MESA) focused on patients with CKD. 25 Another recent reanalysis of scans collected in the whole MESA cohort applying a novel density score showed that it further improves risk discrimination when compared with traditional risk factors and the Agatston score. 26 The gain in discrimination by this score was highly significant but modest (area under receiver operating characteristic curve from 0.700 to 0.711), but the same score allowed a clinically meaningful (+13.9%) improvement in risk reclassification in patients at intermediate risk. Also taking into account the relevant net reclassification improvement of the Agatston score in previous analyses in MESA 11 and in the Rotterdam study, 12 it can be hypothesized that a normal (ie, zero) calcium score as measured by the new density score in patients at intermediate risk may indicate an underlying true risk level low enough to avoid prevention of cardiovascular disease by drug treatment and an elevated score an indication to start or maintain long-term treatment with statins and aspirin. However, a prevention policy based on such an approach still remains to be investigated in a formal clinical trial. 18 The design of a large-scale trial aimed at testing the value of coronary calcium screening in patients at low-tointermediate risk who are not already candidates for statins and aspirin, a large segment of the general population, was published in 2012. 27 Mainly because of the high number of low-to-intermediate risk individuals to be enrolled (≈30 000) and the high cost, such a trial never advanced further than the design phase. Although the new calcium density score 26 or other scores can be useful for increasing the discrimination of coronary calcium, it is unlikely that in the medium-term coronary calcification will be properly tested (ie, incorporated in a clinical trial). The degree of improvement in risk discrimination registered in Criqui's reanalysis of MESA, 26 although not trivial, is per se considered insufficient to change guidelines recommendations.
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Coronary Calcium as a Surrogate End Point in Clinical Trials
A systematic review published in 2009 29 gathered 10 trials testing the effect of various treatments on coronary calcium progression. Five of these trials 30-34 enrolled patients with established cardiovascular disease (n=2135) and 5 5-39 focused on patients with CKD (n=477). The mean weighted annualized coronary calcium score increased both in patients with cardiovascular disease and in those with CKD but without any consistent or reproducible treatment effect of any therapy on this outcome. Therefore, the main conclusion of this meta-analysis was that the change in coronary calcium does not represent a suitable surrogate end point to be applied in randomized clinical trials in patients with cardiovascular or renal disease.
After this meta-analysis, 1 additional trial that tested the effect of an aged garlic extract and a vitamin B complex 40 34 In the 3 placebo-controlled statins trials, the average annualized weighted progression of coronary calcification of patients treated with statins (+15.9%) was similar to that registered in the corresponding placebo arms (+14.0%). More important, in the largest of these trials, in the St Francis Heart Study, 30 there was a clear dissociation between the progression of coronary calcification, which was completely unaffected by treatment and the cardiovascular event rate, which reduced in the active arm of the trial (placebo 9.9%, atorvastatin 6.9%, relative risk reduction, −30%; P=0.08). Similarly, in the 2 studies, which compared 2 statins or a low and a high dose of the same statin (Table S1 ), the progression of calcification was almost identical and largely not significant (P=0.64 and 0.60, respectively). Overall, the lack of effect of statins on coronary calcium is in sharp contrast with the beneficial effect of statins in primary and in secondary prevention. 42 Failure of coronary calcification to capture the solidly established benefit of statins for cardiovascular prevention goes along with biological knowledge that this class of drugs reduces the noncalcified portion of plaques but does not modify, or may even increase, plaque calcification. 14, 43 Atorvastatin significantly reduced noncalcified plaque burden but did not modify the calcification score in a follow-up study in a series of 46 patients at high risk for coronary heart disease. 44 In brief, coronary calcification fails as a surrogate for the effect of statins because it mainly reflects a pathway (calcification), which does not coincide with the pathway conducive to clinical events (occlusive disease; Figure S2 ). In the Intervention as a Goal in Hypertension Treatment trial (INSIGHT), 34 nifedipine once daily sensibly slowed the progression rate of coronary calcification (40% versus 78% over a 3-year follow-up) when compared with an amiloride-hydrochlorothiazide combination (coamilozide), but the favorable effect on coronary calcification by nifedipine failed to translate into a superior clinical benefit. Indeed, in this trial, the occurrence of overall cardiovascular or cerebrovascular complications (combined end point rate: 6.3% for nifedipine and 5.8% for coamilozide) did not differ. 45 Nifedipine per se may favorably interfere with many calcium-dependent events in the formation of atherosclerosis, 46 whereas, in contrast, thiazides may favor mineralization. 47 The unreliability of coronary calcification as a surrogate in trials testing nifedipine and chlortalidone may, therefore, depend on the fact that the differing effect of these drugs on coronary calcification has little bearing for cardiovascular outcomes, which depends on their (shared) favorable interference on the main pathway leading to these outcomes in hypertensive patients (ie, the blood pressure burden on the cardiovascular system; Figure S2 ). Interestingly, the coronary calcium score was substantially reduced by the aged garlic extract/vitamin B complex/l-arginine in the trial by Budoff et al, 40 suggesting a beneficial effect by this therapeutic combination in asymptomatic patients with measurable levels of calcium in the coronary arteries. However, because of the lack of a corresponding trial based on clinical end points, no conclusion can be formulated about the validity of the calcium score as a surrogate for measuring the effect of such a combination on coronary heart disease prevention.
Because of the peculiar propensity to vascular calcification of patients with CKD, trials in this population deserve separate discussion. In this population, 4 additional trials were performed between 2009 and 2014. [48] [49] [50] [51] These trials, all open labeled, and an additional trial published in 2004, 52 which was missed in the previous meta-analysis, added 748 patients to the 477 patients with CKD of the previous meta-analysis, 29 bringing the total to 1125 patients with CKD. Nine trials compared different strategies for controlling hyperphosphatemia (sevelamer or lanthanum carbonate [1 arm in a trial testing also sevelamer] versus calcium-based phosphate binders). One of these trials included also a placebo arm (one a low phosphate diet and another a rosuvastatin arm] or a calcium receptor agonist (cinacalcet) associated with low-dose vitamin D versus flexible doses of vitamin D for controlling hyperparathyroidism. The 9 trials comparing sevelamer (a pleiotropic noncalcium phosphate-binder with lipid-lowering activity) versus calcium-based binders showed a clear-cut reduction in coronary calcium (Figure 1 ). This effect apparently goes along with a new meta-analysis of 7 trials in hemodialysis patients and 1 trial in moderate CKD 35,38,39,53-57 (updating a meta-analysis by Jamal et al 58 ) that shows a lower mortality in patients treated with sevelamer (risk reduction 57% by the random-effect approach and 30% by the fixed-effect approach). However, this apparent benefit is mainly driven (heterogeneity I 2 =89%) by a study in hemodialysis patients showing an astounding 91% risk reduction by sevelamer. Given the high heterogeneity (I 2 =89%) among studies looking at the effect of this drug on mortality (Figure 1 ), the validity of the coronary calcium score as a surrogate of clinical events in studies testing sevelamer still requires further scrutiny in future trials. Lanthanum carbonate, another noncalcium binder, did not slow the progression of calcification in 18 patients treated with this drug when compared with 22 patients treated with calcium-based phosphate binders in a , top) and a study testing the effect of cinacalcet on a composite end point (death, myocardial infarction, hospitalization for unstable angina, heart failure, or a peripheral vascular event; Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events [EVOLVE 59 , bottom]; see also text).
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http://hyper.ahajournals.org/ Downloaded from trial in patients with predialysis CKD by Block et al. 50 More important, no concordance emerged between the effect of cinacalcet (another major drug applied to treat the bone mineral disorder in CKD) on vascular calcification and on the risk for mortality and cardiovascular events. The ADVANCE study (a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in subjects with CKD receiving hemodialysis) 48 showed that the effect of cinacalcet just failed (P=0.07) to meet the primary end point of change in Agatston score but coherently slowed the progression rate in coronary calcification as expressed in volumetric terms (P=0.009) and progression of calcification in heart valves and in the thoracic aorta. On the other hand, no benefit by this drug on mortality and cardiovascular outcomes was registered in the Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) trial, 59 one of the largest drug trials (≈4000 patients) and one with the longest follow-up (≤64 months) ever performed in the hemodialysis population ( Figure 2 ). This discrepancy once again suggests that coronary calcification is an unreliable biomarker of the progression of coronary artery disease also in patients with CKD. Thus, trials in patients with CKD largely fail to provide coherent evidence that coronary calcification is a valid surrogate end point in this population.
Overall, results of studies in the general population, in patients with established coronary heart disease and in patients with CKD do not support the adoption of coronary calcification as a surrogate end point in cardiovascular research. Coronary calcification is probably the biomarker that allows the greater gain in risk reclassification improvement in patients at intermediate risk. However, the usefulness of coronary calcium measurement is restricted to its reclassification power with no substantial gain in risk discrimination or calibration. 9 The hypothesis that the gain in reclassification ability by coronary calcium may be helpful for guiding treatment is negated by available trials. 21, 23 Although better predictive of future cardiovascular events than circulating biomarkers, coronary calcium scanning poses the risk of exposure to ionizing radiation. The effective dose of a calcium score study is ≈5× less (2-3 mSv) than a 64-slice coronary computed tomographic study 60 and with modern technology exposure to a single calcium score examination is roughly equal to average 1-year environmental radiation exposure. Such an exposure should not be overlooked because of the effects of ionizing radiation on human health are cumulative. Warnings to reduce radiation exposure for the diagnosis or the monitoring of cardiovascular disease have been issued by major cardiology societies like the European Society of Cardiology. 61 Although the fundamental mechanism(s) underlying the pathogenesis and progression of coronary calcification and vascular calcification in general have been intensively studied during the past years, 62, 63 the relationship between calcium accumulation and atherosclerosis remains incompletely understood. Vascular biology and imaging studies support the interpretation that calcification is a late, difficult to regress, event in the atherosclerosis process. The effect of treatments that reduce the atherosclerosis burden and the risk for clinical events most often are not captured by the dynamics of vascular calcification. By now, imaging studies aimed at quantifying coronary calcium and vascular calcification should be better restricted to research settings aimed at clarifying the pathobiology of atherosclerosis 64, 65 Vascular Biology of arterial calcification and calcium quantification in the cardiovascular system Calcification in the arterial system may occur either in the intima or in the media of the vascular wall or at both sites. Intima calcification may have a pro-occlusive effect while media calcification may contribute to vascular stiffening. Calcifications are related to unbalance between inhibitors and activators of calcification process in conditions of saturated calcium and phosphate extracellular fluid concentrations. In both calcification types this unbalance activates and recapitulates mechanisms of embryonic bone formation and is similar to endochondral and membranous ossification process [1] . Intimal calcification is a hallmark of advanced atherosclerosis and is an inherently multifactorial process. Aging, hypercholesterolemia, diabetes, hyperphosphatemia represent pro-calcifying stimuli [1;2] which may lead to arterial wall ossification via oxidative stress and inflammation [3] . Osteogenesis driven by inflammatory mechanism is already evident in the early phases of atherosclerosis when studied by molecular imaging techniques [4] . Proinflammatory cytokines -including IL6 and TNF and other cytokines-released by macrophages within the context of the arterial wall stimulate bone morphogenetic proteins (BMP2, BMP4) and Msx2 (muscle segment homeobox gene 2). The activation of Msx2 triggers calcification via paracrine WNT (wingless and integration 1 family) signals and -catenin, which is a co-regulator of a series of transcription factors ( Runx2, osterix, and Sox9) which contribute to transform vascular smooth cells and pericytes into 'osteoblast-like' cells, i.e. cells endowed with the full enzymatic and protein array (alkaline phosphatase, osteocalcin, osteopontin) needed for the formation and the local deposition of apatite nanocrystals [5] . On the other hand the proinflammatory milieu promotes proteolysis via matrix metalloproteinases and cathepsin-S. Proteolysis disrupts elastic lamellae and releases elastin fragments which in turn amplify vascular muscle cells dedifferentiation and calcium deposition. Overall, experimental studies coherently show that inflammatory mechanism(s) herald vascular calcification both in the intimal layer [6] and in smooth muscle cells in the tunica media [1] . Due to the multiple and complex alterations of the hormonal systems regulating calcium and phosphate metabolism [7] , CKD patients have a unique propensity to vascular calcification. Hyperphosphatemia is a relevant pro-calcifying stimulus in advanced CKD. High phosphate stimulates production of reactive oxygen species and activates NF-kB, i.e. a critical pathway mediating the cell response to oxidized LDL, cytokines and other factors thereby favoring the transformation of mesenchymal cells into osteoblasts [8] . On the other hand the role of hyperparathyroidism in vascular calcification remains uncertain for two reasons. First, because PTH -besides having osteoclastogenic properties-has an anabolic action on the bone and, when administered intermittently, actually prevents vascular calcification [9] . Second, because in adynamic bone disease in end stage renal disease PTH suppression rather than hyperparathyroidism associates with vascular calcification [10] .
In brief, various vascular biology studies in vivo and in vitro point to inflammation as an important driver of vascular calcification. Imaging studies in patients with atherosclerosis nicely confirm biological observations. A survey based on positron emission tomography (PET) adopting 18-flourodeoxyglucose (18-FDG) uptake as biomarker of inflamed areas [11] demonstrated that inflammation and calcification rarely overlap in the same plaque indicating that the two phenomena represent distinct stages of atherosclerosis. Furthermore, elegant longitudinal studies combining PET 18-FDG and computed tomography show that inflammation antedates arterial calcification in human atherosclerosis [12] (Figure S1 ). Vascular calcification reflects the progression of inflammation and atherosclerosis and for this reason is considered as a surrogate marker of plaque burden and disease extension. Calcium in the cardiovascular system can be quantified by electron beam computed tomography (EBCT) and by multidetector computed tomography (MDCT). EBCT is faster than MDCT but the second technique has a better spatial resolution and is cheaper. A strong association exists between the presence and severity of calcification in thoracic aorta, in heart valves and in coronary arteries [13] . Even though quantification of calcium in cardiac valves and in the thoracic aorta has been reported in a number of studies and applied as an outcome measure in some clinical trials [14] , the coronary arteries are by far the most investigated cardiovascular territory for calcification in diagnostic, prognostic and therapeutic studies. For this reason, the discussion below will mainly focus on coronary calcium quantification. The Agatston score is calculated by multiplying the lesion area surface in mm 2 by a density factor (ranging between 1 and 4) [15] . Because the density factor is a 4 point categorical scale, changes in this score might not accurately capture changes in coronary calcium. The calcium volume score (CVS) is calculated as the product of calcified voxels in the volume data set (voxel is a volume element which corresponds to a pixel for a given slice thickness) multiplied by the volume of one voxel. CVS estimates calcium in a well-defined volume rather than on a surface and therefore reduces variability between scans [16] . An increase in the Agatston score over time might depend on a pure increase in plaque signal attenuation by calcium rather than on an increase in calcified plaque size while an increase in CVS provides also a volumetric estimate of the calcified plaque. Progression in coronary calcification can be calculated as absolute or percentage change in the Agatston score or in the CVS. There is no golden standard for measuring coronary calcification progression and there is no precise increase which may be used to define worsening in coronary calcification over time. Even though recent studies are increasingly based on volumetric scores, which are methodologically preferable, the vast majority of clinical trials performed so far (Table S1) adopted the Agatston score which is not a volumetric index [15] .
Validity of biomarkers as screening tools and as surrogates of clinical events
Cardiovascular prevention policies demand reliable risk stratification to guide the application of appropriate prevention therapies. Instruments for risk stratification need to be easy to apply and cheap, should accurately predict risk and should have the potential for guiding preventive interventions. Tests for accuracy include risk discrimination (c statistics, area under the ROC curve), calibration (Hosmer-Lemeshow test) and risk reclassification [17] . The previously discussed risk scores which presently inform preventive therapies in the USA and in Europe are based on classical risk factors. These scores are easy to apply and cheap, have good ability for risk discrimination, i.e. provide good rank ordering for cases and non-cases, and reasonably good ability to predict accurately the absolute level of risk that is subsequently observed (calibration) [17] . Importantly, the predictive value of these scores has been confirmed in different prospective cohorts (external validation). In theory the use of these risk estimators should have been compared to non-use in a randomized trial to see whether they may lead to better outcomes by improving underuse while avoiding overuse of preventive therapies. No such trial has been performed for the new ACC/AHA Pooled Cohort Risk Assessment calculator or for the Framingham risk score or the Heartscore or the QRISK. Nonetheless, these risk calculators are pragmatically considered as valid and cost-effective instruments to inform prevention therapies. In other words they have been adopted as the most convenient standard for risk stratification. It is worth remarking that risk calculators serve only to predict risk and therefore do not need to be based on variables which biologically reflect the disease whose risk they are applied to predict. Age is the most important component of the equations wherupon cardiovascular risk scores are based but age per se does not reflect neither cardiovascular disease nor cardiovascular disease severity. We briefly discussed the limitation of current risk scores for individual risk prediction in subjects at intermediate or low risk and alluded to the potential advantage of imaging biomarkers. In order to be considered valid for application as screening tools in cardiovascular prevention, biomarkers should pass the same tests demanded to risk scores (discrimination, calibration, external validation and cost-effectiveness) with the proviso that when tested for accuracy, they should provide prognostic information above and beyond that given by established risk scores [18] . In other words, they should improve the degree of risk discrimination and risk calibration we can achieve simply on the basis of cardiovascular risk scores. Furthermore, imaging biomarkers should also sensibly improve the risk classification provided by the same scores (risk reclassification). Of particular importance, imaging biomarkers and biomarkers in general also need to be tested in a clinical trial to see whether a prevention policy guided by the same biomarkers may improve clinical outcomes [18] . Clinical correlates are indicators that reflect disease severity or activity and as such they are considered as potential surrogates of clinical events for application in clinical research. According to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) [19] a clinical correlate represents a valid surrogate of a corresponding clinical end-point only when (a) it is biologically related to the end point in question, i.e. in the same pathway leading to disease (b) it predicts in proper epidemiological studies the same clinical end point (c) its changes reliably reflect the treatment effects on the corresponding clinical end point in randomized clinical trials. The simple biological association between the clinical correlate and the clinical outcome is insufficient to promote the same correlate to the rank of valid surrogate end point [20] . The list of clinical correlates is virtually innumerable but we have very few validated surrogate end-points. Perhaps the only surrogate endpoints in cardiovascular medicine which reliably predict changes in clinical endpoints in response to experimental interventions are cholesterol for coronary heart disease events and BP for stroke in most clinical settings. Failure of most clinical correlates to qualify as valid surrogates depends on the fact that correlates do not necessarily reflect the actual change in the relevant clinical end point in response to the experimental intervention. A new anti-platelet agent may decrease platelet aggregation in vitro ( a potential marker of the risk for thrombosis) but this effect does not necessarily imply that the use of this drug results in a longer cardiovascular disease free survival. Clinical correlates may fail as surrogate end points for various reasons [21] . They may not be in the main causal pathway of the disease process but simply reflect phenomena in a parallel pathway (Figure S2, II ) and the experimental intervention may modify the clinical correlate but not the main pathway of the disease in question. Second, the surrogate may not be in the pathway whereby the intervention modifies the disease and the intervention may not affect the surrogate (Figure S2, III) . Fourth the surrogate may be in a pathogenic pathway conducive to outcome but the intervention acts by interfering on a separate, second pathogenic pathway that contributes importantly to the outcome (Figure S2, IV) . Combinations of these possibilities can also be envisaged. The validity of a surrogate depends on the clinical or environmental context, i.e. on the particular population or the particular experimental intervention being tested. A classic example of the relevance of the context is bone density. Changes in this biomarker grossly reflect in an inverse fashion the risk of fracture in trials with diphosphonates [22] . However, in a clinical trial in postmenopausal women sodium fluoride, a compound used for the treatment of osteoporosis, increased bone density but increased also the risk of fractures [23] . Using surrogates in clinical research demands caution. Examples of blatant failures of surrogates abound and the case of ventricular premature beats as a surrogate of sudden death in a trial testing flecanide and other Class 1c anti-arrhythmics after myocardial Infarction is often quoted as a classical example of how deceiving surrogates can be. Indeed, when tested in a clinical trial [24] these drugs substantially reduced premature beats but also produced a relevant increase, rather than a decrease, in the risk of sudden death. Such a phenomenon is now attributed to the fact that flecanide interacts with an unexpected translation of the gene coding for the protein-myosin regulatory light chain, a protein which is a crucial component of the contraction of myocardiocytes [25] (Figure S2, IV) . Another example of blatant failure is exercise tolerance by the treadmill test as a surrogate for the risk of death in patients with congestive heart failure [26] . Although increasingly applied, vascular calcification is a surrogate whose validity has yet to be proven. Meta-analytic evidence exists that the coronary calcium score may not be a valid Baseline positron-emission tomography (PET) and sequential computed tomography (CT) of aortic calcification. A, Axial and coronal PET/CT images show focal 18F-flourodeoxyglucose (FDG) uptake in the aorta (yellow arrow). B and C, Baseline and subsequent CT images co-registered to the same locations depicted in the PET/CT images. In the baseline CT images (B) no calcium is seen in the location corresponding to the high FDG uptake (dashed white arrow), on the follow up CT images (C) newly deposited calcium is seen at that same location in the aorta (solid white arrow).
Figure S2
Relationship between surrogates and clinical outcomes. I Valid surrogate. The surrogate is in the main pathogenic pathway and there is a strong association between the surrogate and the outcome. The intervention acts on the pathway towards the surrogate. II The surrogate is in a pathway parallel to the main pathogenic pathway and the intervention affects the surrogate but not the main pathway. III The surrogate is in a pathway parallel to the main pathogenic pathway and the intervention only affects the main pathway. IV surrogate is in a pathogenic pathway conducive to outcome but the intervention acts also a separate, second pathogenic pathway that contributes importantly to the outcome (redrawn from supplementary reference 21) 
